Hepatitis A vaccine

U.S. District Court in Massachusetts Denies 1Globe's Motion for Preliminary Injunction to Enjoin Sinovac's Issuance of Shares

Retrieved on: 
Wednesday, October 17, 2018
RTT, Medicine, Immunology, Communication, Forward-looking statement, Vaccines, Sinovac Biotech, Clinical medicine, Hepatitis A vaccine, Hepatitis

Sinovac welcomes the Court's decision to deny the preliminary injunction requested by 1Globe.

Key Points: 
  • Sinovac welcomes the Court's decision to deny the preliminary injunction requested by 1Globe.
  • Healive, the hepatitis A vaccine manufactured by the Company has passed the assessment under WHO Prequalification procedures in 2017.
  • These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements.
  • Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements.